Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women

NCT03201861 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT03201861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03201861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women
Lead sponsor
RenJi Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
July 27, 2017
Completion date
December 31, 2027
Enrollment
762 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive duct carcinoma of breast, mucinous breast cancer, tubular breast cancer